Juhani Lahdenperä

BiopSense Oy is a Finnish medical technology company that specializes in liquid biopsy services and technology development. The company is based in Jyvaskyla, Finland. BiopSense was founded by Marja Tiirola, Juha Kononen, and Veli-Mikko Puupponen, with Marja Tiirola serving as the CEO since incorporation.

Plexpress offers high-content gene expression analysis for cell biology research, enabling higher throughput and providing more information than competitors' products. Plexpress analysis service is a cost and time efficient solution for large screens in preclinical drug discovery studies, safety assays and yeast studies. Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company's TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. The principal developers of the technology, Hans Soderlund and Jari Rautio, are still closely involved with the company as Chairman of the Scientific Advisory Board and VP of R&D, respectively. Since starting operations in 2008, the company has carried out projects using the TRAC technology in the fields of pharmaceutical development and academic research.

Hermo Pharma Ltd. is a biopharmaceutical company which aims to discover and develop cutting-edge therapeutic approaches for currently untreatable medical needs, particularly in the field of neurology. The company's R&D programs are based on scientifically innovative concepts. These concepts are being developed through preclinical and early clinical development phases with the aim gaining partners prior to late clinical development phases and finally marketing. The company was founded in 2008 by professors Mart Saarma, Eero Castrén, Heikki Rauvala and Dr. Henri Huttunen. The company operates in close collaboration with several academic laboratories affiliated with the University of Helsinki. Hermo Pharma Ltd. operates according to the 'virtual business model'. This means the company outsources the majority of business functions outside of its core business areas, while controlling the key technology assets and strategic partnerships with a small but highly capable group of people managing operations. As the company's overheads are kept lower than traditional biopharmaceutical companies much more of its financial resources can be utilized directly to achieve business goals. Hermo Pharma Ltd. is a privately owned, venture capital backed company. Its current investors include Helsinki University Funds and Seed Fund Vera Ltd.